Health Care Innovation
Commentary
Executive Order On Drug Price Controls Would Backfire
Rumor has it that President Trump will soon issue a sweeping executive order to lower prescription drug prices by fiat. Nothing is set in stone. But the order would reportedly index the government’s reimbursements for medicines to the prices that Britain, France, Canada, and other developed nations pay. Since all those nations ...
Commentary
Patients Will Suffer The Most From The Trump Administration’s Reference Pricing Scheme
The pharmaceutical industry has responded to the Covid-19 pandemic with, arguably, the greatest surge in drug innovation in history. Consider that Remdesivir (produced by Gilead) has already received an emergency use authorization by the FDA for Covid-19. Losmapimod (produced by Fulcrum) is another promising treatment for Covid-19 that is in Phase III trials. And, ...
Commentary
Reforms Should Empower Healthcare Entrepreneurs Not Bureaucrats
Unaffordable healthcare is an unnecessary access barrier that has burdened too many people with financially ruinous debt. Worsening these outcomes, healthcare waste is excessive, and productivity is stagnating. In response, more and more policymakers are favoring reforms that would nationalize healthcare or create a public health insurance option. Further socializing ...
Commentary
Telehealth’s Success During COVID-19 Shows Need to Empower Health Care Innovators
The COVID-19 crisis has tested America’s health care system like no other event in recent memory. One irony during this pandemic is that America has actually experienced the promise of health care innovation in an important way, namely through telehealth. Telehealth allows patients to talk with their doctors online using ...
Business & Economics
Wayne Winegarden – Empowering Entrepreneurs to Address America’s Health Care Challenges
PRI Senior Fellow in Business and Economics Dr. Wayne Winegarden joins us to discuss the latest study in the “Breaking Down Barriers to Opportunity” series, which makes the case that future medical innovation will be hindered unless state and federal policymakers embrace health care entrepreneurship.
Commentary
Do coronavirus numbers show bias in health care? This study’s results will surprise you
African-Americans make up 12.4 percent of the population but have accounted for 23.8 percent of the nation’s COVID-19 deaths, as of June 23. This disparity has gained considerable attention in light of the protests sweeping the country. But the situation is more complicated than it appears. According to a working ...
Business & Economics
NEW STUDY: Future Medical Innovation Will Be Hindered Unless Elected Officials Embrace Health Care Entrepreneurship
As Americans have benefited from tele-health and other innovations thanks to COVID-19 regulatory relief, future medical advances will be stymied unless policymakers remove road blocks that make it difficult for entrepreneurs to develop new technology and for patients to access it, finds the latest study in the Breaking Down Barriers ...
Commentary
Price controls punish U.S. innovators and economy
America’s biopharmaceutical industry dwarfs most other economic sectors. It’s one of our nation’s single biggest job creators, supporting close to a million positions across the country. And its products save countless lives each year. Yet for some reason, politicians in both parties seem determined to snuff it out by imposing ...
Climate Change
Pandemics, Pollution, and Poppycock
By Henry I. Miller, M.S, M.D. and Andrew I. Fillat With the world in the grip of the COVID-19 pandemic, most of the short-term focus is now on how to avoid surges of infections and get the economy functioning so people can go back to work. Hindsight is, of course, ...
Commentary
ICER’s Cost Model Is Not Only Wrong It’s Also Dangerous
There they go again. In the midst of the race for an effective COVID-19 treatment the Institute for Clinical and Economic Review (ICER) has performed an incomplete analysis of remdesivir in order to produce a cost estimate that is, by definition, precisely wrong. Remdesivir, produced by Gilead Sciences Inc., is ...
Executive Order On Drug Price Controls Would Backfire
Rumor has it that President Trump will soon issue a sweeping executive order to lower prescription drug prices by fiat. Nothing is set in stone. But the order would reportedly index the government’s reimbursements for medicines to the prices that Britain, France, Canada, and other developed nations pay. Since all those nations ...
Patients Will Suffer The Most From The Trump Administration’s Reference Pricing Scheme
The pharmaceutical industry has responded to the Covid-19 pandemic with, arguably, the greatest surge in drug innovation in history. Consider that Remdesivir (produced by Gilead) has already received an emergency use authorization by the FDA for Covid-19. Losmapimod (produced by Fulcrum) is another promising treatment for Covid-19 that is in Phase III trials. And, ...
Reforms Should Empower Healthcare Entrepreneurs Not Bureaucrats
Unaffordable healthcare is an unnecessary access barrier that has burdened too many people with financially ruinous debt. Worsening these outcomes, healthcare waste is excessive, and productivity is stagnating. In response, more and more policymakers are favoring reforms that would nationalize healthcare or create a public health insurance option. Further socializing ...
Telehealth’s Success During COVID-19 Shows Need to Empower Health Care Innovators
The COVID-19 crisis has tested America’s health care system like no other event in recent memory. One irony during this pandemic is that America has actually experienced the promise of health care innovation in an important way, namely through telehealth. Telehealth allows patients to talk with their doctors online using ...
Wayne Winegarden – Empowering Entrepreneurs to Address America’s Health Care Challenges
PRI Senior Fellow in Business and Economics Dr. Wayne Winegarden joins us to discuss the latest study in the “Breaking Down Barriers to Opportunity” series, which makes the case that future medical innovation will be hindered unless state and federal policymakers embrace health care entrepreneurship.
Do coronavirus numbers show bias in health care? This study’s results will surprise you
African-Americans make up 12.4 percent of the population but have accounted for 23.8 percent of the nation’s COVID-19 deaths, as of June 23. This disparity has gained considerable attention in light of the protests sweeping the country. But the situation is more complicated than it appears. According to a working ...
NEW STUDY: Future Medical Innovation Will Be Hindered Unless Elected Officials Embrace Health Care Entrepreneurship
As Americans have benefited from tele-health and other innovations thanks to COVID-19 regulatory relief, future medical advances will be stymied unless policymakers remove road blocks that make it difficult for entrepreneurs to develop new technology and for patients to access it, finds the latest study in the Breaking Down Barriers ...
Price controls punish U.S. innovators and economy
America’s biopharmaceutical industry dwarfs most other economic sectors. It’s one of our nation’s single biggest job creators, supporting close to a million positions across the country. And its products save countless lives each year. Yet for some reason, politicians in both parties seem determined to snuff it out by imposing ...
Pandemics, Pollution, and Poppycock
By Henry I. Miller, M.S, M.D. and Andrew I. Fillat With the world in the grip of the COVID-19 pandemic, most of the short-term focus is now on how to avoid surges of infections and get the economy functioning so people can go back to work. Hindsight is, of course, ...
ICER’s Cost Model Is Not Only Wrong It’s Also Dangerous
There they go again. In the midst of the race for an effective COVID-19 treatment the Institute for Clinical and Economic Review (ICER) has performed an incomplete analysis of remdesivir in order to produce a cost estimate that is, by definition, precisely wrong. Remdesivir, produced by Gilead Sciences Inc., is ...
